Please try another search
For the six months ended 30 June 2020, Akcea Therapeutics Inc revenues decreased 80% to $38.5M. Net loss before extraordinary items increased from $10.1M to $94.1M. Revenues reflect Research and development and license revenue under segment decrease of 96% to $6.9M. Higher net loss reflects Net loss share from commercial activitie decrease of 49% to $10.5M (income), Selling/General/Admin. E increase of 2% to $70.4M (expense).
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Revenue | 22.38 | 16.07 | 277.48 | 20.62 |
Gross Profit | 17.33 | 11.29 | 272.45 | 18.22 |
Operating Income | -51.09 | -45.26 | 83.16 | -32.59 |
Net Income | -49.58 | -42.85 | 82.41 | -31.5 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Assets | 527.94 | 559.92 | 599.25 | 383.17 |
Total Liabilities | 48.91 | 50.23 | 56.25 | 57.68 |
Total Equity | 479.03 | 509.69 | 543 | 325.49 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 9 Months |
Cash From Operating Activities | -77.53 | -44.1 | 223.82 | 15.09 |
Cash From Investing Activities | -97.25 | -101.32 | 8.43 | 42.13 |
Cash From Financing Activities | 3.57 | 1.87 | -11.93 | -14.32 |
Net Change in Cash | -171.12 | -143.55 | 220.41 | 42.88 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review